Iressa as Second Line Therapy in Advanced NSCLC-Asia

Summary

This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational sites throughout the Asia Pacific region that have expertise in treating patients with NSCLC.

Timeline

Start

2005-09

Primary completion

2007-05

Completion

2009-02

Drugs

Indications